A Risk-Group Classification Model in Patients with Bladder Cancer Under Neoadjuvant Cisplatin-Based Combination Chemotherapy

References

• Richters A , AbenKKH, KiemeneyLALM. The global burden of urinary bladder cancer: an update. World J. Urol.38(8), 1895–1904 (2020).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G , FedericoP, DePlacido S, BuonerbaC. Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: a systematic review. Crit. Rev. Oncol. Hematol.96(3), 534–541 (2015).
   PubMed Web of Science ®Google Scholar
• Fernández MI , BrausiM, ClarkPEet al. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer. World J. Urol.37(1), 3–13 (2018).
   PubMed Web of Science ®Google Scholar
• Anon . Survival Rates for Bladder Cancer (2016). www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging/survival-rates.html.
   Google Scholar
• Ferro M , DiLorenzo G, VartolomeiMDet al. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. World J. Urol.38(1), 143–150 (2020).
   PubMed Web of Science ®Google Scholar
• Capece M , SpiritoL, RoccaR Laet al. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC): a retrospective analysis. Arch. Ital. di Urol. e Androl.92(1), 17–20 (2020).
   Web of Science ®Google Scholar
• Satyanarayana R , KallingalG, ParekhD. Current status of robotic and laparoscopic techniques in radical cystectomy and diversion procedures for bladder cancer: review. Minerva Urol. Nefrol.66(1), 1–14 (2014).
   PubMed Web of Science ®Google Scholar
• Buscarini M , PasinE, SteinJP. Complications of radical cystectomy. Minerva Urol. Nefrol.59(1), 67–87 (2007).
   PubMedGoogle Scholar
• Locke JA , PondGR, SonpavdeGet al. Cisplatin- versus non–cisplatin-based first-line chemotherapy for advanced urothelial carcinoma previously treated with perioperative cisplatin. Clin. Genitourin. Cancer14(4), 331–340 (2016).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G , BuonerbaC, BellelliTet al. Third-line chemotherapy for metastatic urothelial cancer: a retrospective observational study. Med. (United States)94(51), (2015).
   Google Scholar
• Fuhrmann C , StruckJP, IvanyiPet al. Checkpoint inhibition for metastatic urothelial carcinoma after chemotherapy—real-world clinical impressions and comparative review of the literature. Front. Oncol.10, 808 (2020).
   PubMed Web of Science ®Google Scholar
• Witjes JA , BruinsHM, CathomasRet al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur. Urol.79(1), 82–104 (2021).
   PubMed Web of Science ®Google Scholar
• Necchi A , AnichiniA, RaggiDet al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol.36(34), 3353–3360 (2018).
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol.48(2), 202–206 (2005).
   PubMed Web of Science ®Google Scholar
• Sherif A , HolmbergL, RintalaEet al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur. Urol.45(3), 297–303 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenblatt R , SherifA, RintalaEet al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur. Urol.61(6), 1229–1238 (2012).
   PubMed Web of Science ®Google Scholar
• Fallah J , Diaz-MonteroCM, RaymanPet al. Myeloid-derived suppressor cells in nonmetastatic urothelial carcinoma of bladder is associated with pathologic complete response and overall survival. Clin. Genitourin. Cancer18(6), 500–508 (2020).
   PubMed Web of Science ®Google Scholar
• Rubino S , KimY, ZhouJet al. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J. Urol.1–9 (2020).
   PubMed Web of Science ®Google Scholar
• Regnier P , DeLuca V, BrunelleSet al. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy and post cystectomy complications. Minerva Urol. Nefrol. (2020).
   Google Scholar
• Psutka SP , CarrascoA, SchmitGDet al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer120(18), 2910–2918 (2014).
   PubMed Web of Science ®Google Scholar
• Vollmer T , SchlickeiserS, AminiLet al. The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. Sci. Transl. Med.13(576), (2021).
   PubMed Web of Science ®Google Scholar
• Iyer G , TullyCM, ZaborECet al. Neoadjuvant gemcitabine-cisplatin plus radical cystectomy-pelvic lymph node dissection for muscle-invasive bladder cancer: A 12-year experience. Clin. Genitourin. Cancer18(5), 387–394 (2020).
   PubMed Web of Science ®Google Scholar
• Black AJ , ZargarH, Zargar-ShoshtariKet al. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol. Oncol. Semin. Orig. Investig.38(1), 3.e17–3.e27 (2020).
   PubMed Web of Science ®Google Scholar
• Ferro M , DeCobelli O, BuonerbaCet al. Modified Glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical cystectomy: a multicenter experience. Med. (US)94(42), e1861 (2015).
   PubMed Web of Science ®Google Scholar
• Tamalunas A , BuchnerA, KretschmerAet al. Impact of routine laboratory parameters in patients undergoing radical cystectomy for urothelial carcinoma of the bladder: a long-term follow-up. Urol. Int.104(7–8), 551–558 (2020).
   PubMed Web of Science ®Google Scholar
• Vale C . Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet361(9373), 1927–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Pfister C , GravisG, FléchonAet al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER Trial Seconda. Eur. Urol.79(2), 214–221 (2021).
   PubMed Web of Science ®Google Scholar
• Necchi A , RaggiD, GallinaAet al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur. Urol.77(4), 439–446 (2020).
   PubMed Web of Science ®Google Scholar
• Liang Z , ChenY, WangLet al. CYP27A1 inhibits bladder cancer cells proliferation by regulating cholesterol homeostasis. Cell Cycle18(1), 34–45 (2019).
   PubMed Web of Science ®Google Scholar
• Wang C , HeH, FangW. Oncogenic roles of the cholesterol metabolite 25-hydroxycholesterol in bladder cancer. Oncol. Lett.19(6), 3671–3676 (2020).
   PubMed Web of Science ®Google Scholar
• Teleka S , HäggströmC, NagelGet al. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: a prospective pooled cohort study of 800,000 men and women. Int. J. Cancer143(12), 3071–3082 (2018).
   PubMed Web of Science ®Google Scholar